Unique pulmonary antigen presentation may call  for an alternative approach toward lung cancer immunotherapy by Chang, Stephanie et al.




Unique pulmonary antigen presentation may call
for an alternative approach toward lung cancer
immunotherapy
Stephanie Chang
Washington University School of Medicine in St. Louis
Xue Lin
Washington University School of Medicine in St. Louis
Ryuji Higashikubo
Washington University School of Medicine in St. Louis
Kelsey Toth
Washington University School of Medicine in St. Louis
Andrew E. Gelman
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Chang, Stephanie; Lin, Xue; Higashikubo, Ryuji; Toth, Kelsey; Gelman, Andrew E.; Kreisel, Daniel; and Krupnick, Alexander S.,




Stephanie Chang, Xue Lin, Ryuji Higashikubo, Kelsey Toth, Andrew E. Gelman, Daniel Kreisel, and
Alexander S. Krupnick
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2515
www.landesbioscience.com OncoImmunology e23563-1
OncoImmunology 2:3, e23563; March 2013; © 2013 Landes Bioscience
 POInt-Of-VIew POInt-Of-VIew
Keywords: natural killer cells, lung can-
cer, mucosal antigen presentation, immu-
notherapy, adoptive immune system
Submitted: 01/04/13
Accepted: 01/09/13
*Correspondence to: Alexander S. Krupnick; 
Email: krupnicka@wudosis.wustl.edu
Citation: Chang S, Lin X, Higashikubo R, Toth 
K, Gelman AE, Kreisel D. Unique pulmonary 
antigen presentation may call for an alterna-
tive approach for lung cancer immunotherapy. 
OncoImmunology 2013; 2:e23563; http://dx.doi.
org/10.4161/onci.23563
Unlike other tumors, lung cancer appears to be poorly sensitive to 
immunotherapy. We have recently dem-
onstrated an alternative pathway of lung 
cancer immunosurveillance. Our data 
indicate a failure of the adaptive immune 
system to mediate the immunosurveil-
lance of lung cancer and emphasize the 




A documented clinical effort to employ 
immunotherapy against malignancies can 
be traced back to the late 1800s, when the 
New York surgeon William Coley started 
to treat patients with a concoction of 
inactivated bacterial products known as 
“Coley’s toxin.”1 Over the last century the 
immunotherapeutic approaches against 
both solid and hematological tumors have 
become more refined, due to an improved 
understanding of the tumor immune 
response. The recognition that malignant 
cells (over)express antigenic proteins that 
are not present, or are present in relatively 
low amounts, in normal tissue has brought 
forth immunotherapeutic strategies focus-
ing on T lymphocytes that target such 
tumor-associated antigens (TAAs). TAAs 
are products of mutated cellular genes or 
viral proteins that are not expressed in 
physiological conditions by somatic cells. 
Such antigens are expressed in herpesvi-
rus- or retrovirus-induced malignancies 
such as Burkitt’s lymphoma.2 Cancer-
testes antigens are expressed on germ (but 
not on somatic) cells, except in the context 
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of malignant transformation. NY-ESO-1 
is a prototypic cancer-testes antigen origi-
nally identified in esophageal adenocarci-
noma,3 and melanoma-associated antigen 
A3 (MAGE-A3) is a similar antigen that 
has been actively studied as a target for 
immunotherapy.4 Alternatively, normal 
cellular proteins, such as glycoprotein 100 
(gp100) and melanoma antigen recog-
nized by T cells 1 (MART-1), can be over-
expressed on malignant cells and induce 
a tumor-specific immune response.5 
Incidental observations indicating that a 
selected group of individuals with circu-
lating antibodies against melanoma-asso-
ciated antigens may have a more indolent 
disease course3 suggest that manipulating 
the immune system of cancer patients may 
offer therapeutic applications.
In a series of elegant clinical trials, 
Rosenberg and colleagues demonstrated 
that autologous T cells, be they derived 
from tumor-infiltrating lymphocytes or 
engineered to express a melanoma-reactive 
T-cell receptor (TCR)—expanded ex vivo 
and then reinfused into patients—can 
mediate tumor regression and, some-
times, a durable tumor-specific immune 
response.6,7 It has recently been demon-
strated that the ex vivo modification and 
reinfusion of autologous T cells expressing 
a chimeric TCR targeting a B-cell antigen 
I is particularly efficient for the treatment 
of chronic lymphocytic leukemia.8 Other 
immunotherapeutic strategies rely on 
tumor “vaccines,” resulting in the expan-
sion of TAA-reactive T lymphocytes in 
vivo. Sipuleucel-T (Provenge™) is a thera-
peutic vaccine recently approved by FDA 
for use in metastatic hormone-refractory 
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inhibit all antitumor immune responses, 
giving the false impression that this malig-
nancy remains “invisible” to the adaptive 
immune system. An alternative hypothesis 
to explain the aforementioned discrepancy 
may relate to immunoregulation associated 
with mucosal antigen presentation.
Mucosal tolerance plays an important 
role in normal physiology and homeostasis 
of barrier organs, preventing exaggerated 
immune responses to innocuous environ-
mental antigens.22 Multiple experimental 
models have demonstrated that mucosal 
antigen delivery results in the generation 
of CD4+ Tregs,23 but the effects on cyto-
toxic T lymphocytes (CTLs), most of 
which are CD8+ T cells, remain poorly 
defined. Some authors have reported that 
mucosal antigen presentation can acti-
vate CD8+ T lymphocytes,24 while others 
have demonstrated a downregulation of 
CD8+ T-cell responses under similar con-
ditions.25 In order to directly address this 
issue in a model of lung cancer-specific 
antigen presentation, we generated murine 
bone marrow chimeras with animals bear-
ing a mixture of CD8+ T cells derived from 
OT-1 ovalbumin-specific transgenic mice 
(on a CD45.2+ background) and wild-type 
CD45.1+ congenic mice. Such a system 
allowed us to identify ovalbumin-reactive 
T cells as CD8+CD45.2+CD45.1− cells. 
After an engraftment period of 3 mo, mice 
were randomized into 3 groups. Group #1 
was injected with saline while Group #2 
was s.c. administered with 1 × 106 cells 
derived from ovalbumin-expressing Lewis 
lung carcinoma cells (LLC-ova), kindly 
provided by D. Gabrilovich.26 Group #3 
received an intratracheal injection of LLC-
ova cells. Such a system, relying on ovalbu-
min as a surrogate TAA, allows for tracking 
tumor-specific immune responses. All 
mice were sacrificed two weeks later and 
splenocytes analyzed by flow cytometry. 
Of CD8+ T cells from mixed bone mar-
row chimeras in Group #1, 66.5% were 
of OT-1 origin with a non-statistically 
significant decrease to 58% in animals 
injected with tumor cells s.c. (Group #2). 
Mice injected with intratracheal LLC-ova 
cells (Group #3), however, demonstrated 
a significant decrease in the propor-
tion of OT-1 T cells to 37.4% (Fig. 1B). 
Furthermore, upon overnight stimulation 
with ovalbumin, OT-1 T cells from mice 
The second possibility seems unlikely, as 
one of the earliest trials based on ex vivo 
expanded peripheral blood-derived leuko-
cytes or lymphokine activated killer cells 




All clinical trials successfully testing 
immunotherapeutic strategies in cancer 
patients have been based on initial studies 
in small animal models. The recent clinical 
success of immunotherapy in the treatment 
of malignant melanoma,14 for example, 
can be directly linked to preclinical studies 
demonstrating the success of such therapy 
in rodents.17 Alternatively, it can be argued 
that animal models of immunotherapy 
are developed as a result of observational 
studies focusing on naturally-occurring 
mechanisms of immunosurveillance. 
Surprisingly, the immunosurveillance of 
lung cancer has been poorly investigated. 
To address this deficiency, we have recently 
undertaken a series of studies focusing on 
the mechanisms of immunosurveillance 
and immunoregulation of lung cancer.18 
Using a well-established model of ure-
thane-induced primary lung cancer, we 
have demonstrated that bone marrow-
derived cells play a critical role in the elim-
ination of lung cancer cells. However, to 
our surprise, T cells played no role in this 
process. Identical tumor burdens charac-
terized indeed wild-type and mice lacking 
the adaptive immune system (Fig. 1A). 
This situation differs significantly from 
that observed in other types of cancer, such 
as fibrosarcoma or gastrointestinal stromal 
tumor, two settings in which T lympho-
cytes play a critical role in both immuno-
surveillance and therapeutic responses.19,20 
The reasons for this are difficult to under-
stand since lung cancer, just like melanoma 
and fibrosarcoma, expresses TAAs11 that 
should, at least in theory, activate antigen-
specific T lymphocytes. One possibility is 
that lung cancer contains a high prevalence 
of regulatory T lymphocytes, especially 
CD4+CD25+ regulatory T cells (Tregs). 
In fact, the earliest description of tumor-
infiltrating Tregs was made in human lung 
cancer.21 It is thus possible that the rapid 
infiltration of lung tumors with Tregs may 
prostate cancer patients. It relies on the 
isolation of autologous dendritic cells, 
their loading with the prostate-specific 
antigen prostatic acid phosphatase (PAP) 
ex vivo, and their re-administration to 
patients. Such a treatment has been shown 
to provide a survival advantage due to 
the activation of PAP-reactive T lym-
phocytes.9 Other strategies for activating 
TAA-reactive T lymphocytes, such as the 
administration of MAGE-A3-derived 
peptides along with an adjuvant, have also 
demonstrated some degree of efficacy in 
malignant melanoma patients.10
Limited Success  
of Immunotherapy  
against Lung Cancer
In contrast to melanoma and prostate 
cancer, limited success has been reported 
for immunotherapeutic strategies against 
lung cancer, in particular for approaches 
targeting T lymphocytes, including vac-
cination. Mucin 1 (MUC1) is a trans-
membrane protein expressed on epithelial 
cells and overexpressed in some lung can-
cers.11 A randomized Phase IIB trial test-
ing a liposomal vaccine targeting MUC1 
in patients with Stage IIIB and IV non-
small cell lung carcinoma (NSCLC) has 
recently been completed, demonstrating 
only a marginal, non-statistically signifi-
cant improved in survival as compared 
with control patients.12 A vaccine targeting 
MAGE-A3 has recently been evaluated 
in a Phase II trial enrolling lung cancer 
patients affected by Stage Ib or II tumors 
after resection.13 Despite the fact that 
MAGE-A3 was expressed by all patients, 
no statistically significant increase in sur-
vival was noted in this study. Unlike the 
case of malignant melanoma,14 immu-
notherapeutic approaches based on the 
blockade of immune checkpoint dem-
onstrated minimal efficacy in NSCLC 
patients,15 albeit in an early phase trial. 
Such a reported lack of efficacy of immu-
notherapy against lung cancer may stem 
from a significant discrepancy in the num-
ber of trials enrolling NSCLC patients as 
compared with individuals affected by 
other tumors, such as melanoma, but it 
may also reflect the fact that vaccines 
against lung cancer, or lung cancer immu-
notherapy in general, is not efficacious. 
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constitute the main immunological bar-
rier to the development of lung cancer, 
and might therefore constitute a better 
targer for lung cancer immunotherapy. 
In order to directly address this question, 
we generated AJ/B6 F1 chimeric mice, 
which have a susceptibility to lung can-
cer that lays somewhat in between highly 
susceptible AJ and resistant B6 mice. 
Upon treatment with urethane, AJ/B6 F1 
mice were randomized into three groups. 
Group #1 was injected with 1 × 106 
freshly isolated NK cells from B6 mice, 
while Groups #2 and #3 were treated with 
saline or NK cells isolated from AJ mice, 
respectively. All animals were injected i.p. 
every two weeks for total of four months 
and tumor burden was determined at sac-
rifice as previously described.18 Mice in 
Group #1 had the lowest tumor burden, 
suggesting that exogenously adminis-
tered NK cells can control the develop-
ment and/or progression of lung cancer, 
of lung cancer, we focused our atten-
tion on innate immune mechanisms. 
Unlike T cell-deficient mice, mice lack-
ing natural killer (NK) cells exhibited a 
statistically significant increase in lung 
cancer incidence and overall tumor bur-
den as compared with wild-type animals 
(Fig. 2A).18 Furthermore, we observed 
a negative correlation between NK-cell 
cytotoxicity and the susceptibility of mice 
to carcinogen-induced lung cancer. NK 
cells from AJ and 129 mice, for example, 
demonstrated minimal cytolytic activ-
ity against lung cancer cells in vitro, and 
these two strains of mice were found to 
be highly susceptible to the develop-
ment of carcinogen-induced lung can-
cer.18 NK cells from the B6 mouse strain, 
conversely, exhibited high levels of lung 
cancer-specific cytotoxicity and B6 mice 
were resistant to lung cancer carcino-
genesis (Fig. 2B).18 These data suggest 
that NK cells rather than T lymphocytes 
in Group #3 demonstrated decreased inter-
feron γ (IFNγ) production, suggesting the 
development of anergy to antigen-specific 
stimulation. These data are in line with 
previous reports demonstrating that the 
mucosal delivery of antigens can down-
regulate systemic CD8+ T-cell immune 
responses.25,27 It is thus possible that the 
poor efficiency of TAA-based vaccines in 
lung cancer patients may be due to either 
the absence of TAA-specific CD8+ cyto-
toxic T lymphocytes as a result of deletion 
or sequestration, or to alternative forms of 
T-cell inactivation associated with mucosal 
antigen presentation.
The Innate Immune System  
Plays a Dominant Role  
in the Immunosurveillance  
of Lung Cancer
Since we determined that the adaptive 
immune system fail to control the growth 
Figure 1. Involvement of the adaptive immune system in the control of lung cancer. (A) no difference in lung tumor burden is evident in B6 wild-type, 
t cell-deficient nude or Rag2−/− mice treated with urethane. (B) Analysis of splenocytes from chimeric mice demonstrates a relative deficiency of Ot-1 
ovalbumin-reactive CD8+ t cells in mice bearing lung tumors as compared with those subcutaneous tumors in the flank. A decreased production of 
interferon γ (Ifnγ) is also evident among Ot-1 CD8+ t cells in lung tumor-bearing mice. (A) is modified from ref. 18.
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present compelling data suggesting that 
immunotherapeutic strategies that are 
(at least in part) successful against other 
solid tumors may not be applicable to lung 
cancer without significant refinement. We 
also demonstrate a prominent role for NK 
cells in the primary immunosurveillance 
of lung cancer as well as their potential 
as an immunotherapeutic tool against 
this dreadful disease. We therefore sug-
gest that a different immunotherapeutic 
approach, perhaps closer to that employed 
against hematological tumors such as 
acute myeloid leukemia,29 may offer an 
improved efficacy for the treatment of 
lung cancer.
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Conclusions
Lung cancer is the number one cancer-
related cause of death in the Western 
world, being associated with a higher dis-
ease-specific mortality then prostate, colon 
and breast cancer combined.30 Despite this 
fact, the development of immunothera-
peutic approaches against lung cancer lags 
far behind that of strategies to exploit the 
immune system against tumors, such as 
malignant melanoma. Our data and those 
of others27 demonstrate that the adaptive 
immune system plays a limited role in the 
control of lung cancer growth. This may 
be due to the highly immunosuppressive 
environment created by lung cancer cells 
as well as to the unique immunological 
properties of the lung, which alter TAA-
reactive T lymphocytes. Nevertheless, we 
and individual differences in NK cyto-
toxicity could be utilized as a therapeutic 
application (Fig. 2C). Very early studies 
by Rosenberg’s group demonstrated that 
at least one patient affected by primary 
lung adenocarcinoma exhibited a par-
tial response to the reinfusion of autolo-
gous LAKs expanded ex vivo, which are 
highly enriched in activated NK cells.16 
Most subsequent clinical trials by the 
same group, however, have focused on 
melanoma. One recent Phase I clinical 
trial from Greece demonstrated that the 
administration of haploidentical NK cells 
expanded ex vivo may offer clinical effi-
cacy against unresectable lung cancer.28 
However, unlike the case of hematologic 
malignancies,29 NK cell-based immuno-
therapeutic approaches against lung can-
cer are poorly explored.
Figure 2. Involvement of natural killer cells in the control of lung cancer. (A) the depletion of natural killer (nK) cells leads to an increased incidence of 
carcinogen-induced lung cancer and increased tumor burden in mice. (B) nK cells from lung cancer-resistant B6 mice demonstrate more robust lung-
cancer specific cytotoxicity than cells from lung cancer-susceptible 129 and A/J animals. (B) the adoptive transfer of nK cells from B6 mice decreases 
tumor burden in urethane-treated mice. (A and B) are modified from ref. 18.
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